(3-(4-(CARBOXYLATOMETHOXY)PHENYL)-2-HYDROXYPROPYL)HYDROXY-MERCURATE(1-), SODIUM Toxicity Data With Reference
1. | | ivn-rbt LDLo:7 mg/kg | | JPETAB Journal of Pharmacology and Experimental Therapeutics. 41 (1931),21. |
(3-(4-(CARBOXYLATOMETHOXY)PHENYL)-2-HYDROXYPROPYL)HYDROXY-MERCURATE(1-), SODIUM Consensus Reports
Mercury and its compounds are on the Community Right-To-Know List.
(3-(4-(CARBOXYLATOMETHOXY)PHENYL)-2-HYDROXYPROPYL)HYDROXY-MERCURATE(1-), SODIUM Safety Profile
(3-(4-(CARBOXYLATOMETHOXY)PHENYL)-2-HYDROXYPROPYL)HYDROXY-MERCURATE(1-), SODIUM Standards and Recommendations
OSHA PEL: CL 0.1 mg(Hg)/m3 (skin)
ACGIH TLV: TWA 0.1 mg(Hg)/m3 (skin); BEI: 35 µg/g creatinine total inorganic mercury in urine preshift; 15 µg/g creatinine total inorganic mercury in blood at end of shift at end of workweek.
DFG MAK: Confirmed Animal Carcinogen with Unknown Relevance to Humans
NIOSH REL: (Mercury, Aryl and Inorganic) CL 0.1 mg/m3 (skin)